Aptar Q1 sales rise 11%, beat estimates; EPS falls as prescription sales decline

AptarGroup

30/04/2026 22:16

Overview

Drug delivery and dispensing firm's Q1 sales rose 11%, beating analyst expectations

Adjusted EPS for Q1 beat consensus but declined 8% yr/yr

Company returned $131 mln to shareholders via buybacks and dividends

Outlook

Aptar expects Q2 2026 adjusted EPS of $1.32 to $1.40

Company anticipates growth across all segments in Q2, except for emergency medicine destocking in Pharma

Aptar remains mindful of potential supply-chain uncertainties in the coming quarter

Result Drivers

INJECTABLES DEMAND - Pharma injectables division delivered strong double-digit growth, driven by demand for GLP-1, biologics and antithrombotics

EMERGENCY MEDICINE DESTOCKING - Prescription division sales declined due to reduced sales in emergency medicine category and tough comparison with strong prior-year quarter

BEAUTY AND CLOSURES VOLUME GROWTH - Consumer dispensing segment saw volume growth in Beauty and Closures, supported by demand in fragrance and beverage applications

Company press release: ID:nBwNDdFna

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$982.90 mln
$955.28 mln (6 Analysts)
Q1 Adjusted EPS
Beat
$1.19
$1.15 (7 Analysts)
Q1 EPS
$1.12
Q1 Net Income
$73 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

Wall Street's median 12-month price target for Aptargroup Inc is $153.00, about 24.5% above its April 29 closing price of $122.90

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 22 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)